Juno Therapeutics Inc (JUNO) EVP Sells $81,647.36 in Stock

Juno Therapeutics Inc (NASDAQ:JUNO) EVP Robert Azelby sold 1,816 shares of the company’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $44.96, for a total value of $81,647.36. Following the completion of the sale, the executive vice president now owns 70,832 shares of the company’s stock, valued at $3,184,606.72. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Robert Azelby also recently made the following trade(s):

  • On Thursday, November 2nd, Robert Azelby sold 6,666 shares of Juno Therapeutics stock. The stock was sold at an average price of $54.95, for a total value of $366,296.70.

Shares of Juno Therapeutics Inc (NASDAQ:JUNO) traded down $1.34 on Friday, hitting $48.75. The stock had a trading volume of 1,510,000 shares, compared to its average volume of 2,330,000. Juno Therapeutics Inc has a 1 year low of $18.90 and a 1 year high of $63.45. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $5,570.00, a P/E ratio of -14.38 and a beta of 2.32.

Juno Therapeutics (NASDAQ:JUNO) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.07. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The firm had revenue of $44.80 million for the quarter, compared to the consensus estimate of $18.12 million. During the same quarter in the prior year, the business earned ($0.57) earnings per share. The company’s revenue was up 115.4% compared to the same quarter last year. equities research analysts expect that Juno Therapeutics Inc will post -4.02 EPS for the current fiscal year.

Several research analysts have recently commented on JUNO shares. Morgan Stanley reissued an “equal weight” rating and issued a $43.00 price target (up from $27.00) on shares of Juno Therapeutics in a research report on Friday, October 6th. Goldman Sachs Group reissued a “neutral” rating and issued a $44.00 price target on shares of Juno Therapeutics in a research report on Friday, October 6th. Maxim Group reissued a “buy” rating and issued a $56.00 price target (up from $34.00) on shares of Juno Therapeutics in a research report on Monday, October 9th. Cowen reaffirmed a “buy” rating and set a $49.00 target price on shares of Juno Therapeutics in a research report on Friday, October 27th. Finally, Citigroup reaffirmed a “buy” rating and set a $59.00 target price on shares of Juno Therapeutics in a research report on Tuesday, October 31st. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $46.70.

Several institutional investors and hedge funds have recently modified their holdings of JUNO. Teachers Advisors LLC boosted its position in Juno Therapeutics by 5.8% during the first quarter. Teachers Advisors LLC now owns 64,365 shares of the biopharmaceutical company’s stock worth $1,428,000 after purchasing an additional 3,531 shares in the last quarter. Russell Investments Group Ltd. boosted its position in Juno Therapeutics by 64.6% during the second quarter. Russell Investments Group Ltd. now owns 17,684 shares of the biopharmaceutical company’s stock worth $528,000 after purchasing an additional 6,943 shares in the last quarter. Canada Pension Plan Investment Board boosted its position in Juno Therapeutics by 70.1% during the second quarter. Canada Pension Plan Investment Board now owns 160,600 shares of the biopharmaceutical company’s stock worth $4,800,000 after purchasing an additional 66,200 shares in the last quarter. State of Wisconsin Investment Board boosted its position in Juno Therapeutics by 1.7% during the second quarter. State of Wisconsin Investment Board now owns 12,562 shares of the biopharmaceutical company’s stock worth $375,000 after purchasing an additional 210 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Juno Therapeutics by 7.3% during the second quarter. Bank of New York Mellon Corp now owns 281,858 shares of the biopharmaceutical company’s stock worth $8,425,000 after purchasing an additional 19,057 shares in the last quarter. Hedge funds and other institutional investors own 69.94% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Juno Therapeutics Inc (JUNO) EVP Sells $81,647.36 in Stock” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/13/robert-azelby-sells-1816-shares-of-juno-therapeutics-inc-juno-stock.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Insider Buying and Selling by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply